KRAS
A gene frequently mutated in cancers; long considered 'undruggable' until recent targeted therapies.
Coverage of KRAS is holding steady : 15 signals on the latest tracked day, up 67% from its three-week baseline of 9, across 5 domains (unchanged from a week ago). That makes it the #38 most-covered of the 337 concerns we track.
What’s changed
6 of the last 7 tracked days ran above the three-week baseline — a sustained move, not a one-day spike.
- GenFleet's KRAS G12D Lung Cancer Drug Shows Strong Phase II Results, Advancing to First Global Phase III Trial · TipRanks · 2026-09-21
- Computational identification and characterization of high-risk human KRAS nsSNPs: Impacting structure, ligand binding, and cancer prognosis · Journal of Genetic Engineering and Biotec · 2026-09-21
- PADI-Dependent Mitochondrial Adaptation Drives Resistance to KRAS Inhibitors · crc-digest · 2026-09-20
- Pulmonary artery enlargement observed during bevacizumab therapy in KRAS-mutant colon cancer · crc-digest · 2026-09-18
- Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer · Cancer Cell · 2026-09-18
- Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial. · Nat Med · 2026-09-15
What the reporting says
It shows up alongside Colorectal Cancer (131), Lung Cancer (63 — acquisition ×2), Pancreatic Cancer (49), KRAS Mutant (45), Egfr (37), Immunotherapy (31), Braf (22), Pdac (21).
Two steps out: ctDNA (through Colorectal Cancer, 122 shared stories on the weaker link); Overall Survival (through Colorectal Cancer, 71 shared stories on the weaker link); Wang (through Colorectal Cancer, 71 shared stories on the weaker link); AI (through Colorectal Cancer, 67 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 151 separate days — concentrated in Oncology and Pubmed Targeted.